FDA approves 1st new TB drug in 40 years - WXOW News 19 La Crosse, WI – News, Weather and Sports |

FDA approves 1st new TB drug in 40 years

Posted:
  • HealthMore>>

  • US eating habits improve a bit _ except among poor

    US eating habits improve a bit _ except among poor

    Wednesday, September 3 2014 1:22 AM EDT2014-09-03 05:22:21 GMT
    A new study says Americans' eating habits have improved - except among the poor.More >>
    Americans' eating habits have improved - except among the poor, evidence of a widening wealth gap when it comes to diet. Yet even among wealthier adults, food choices remain far from ideal, a 12-year study found.More >>
  • Group says world is losing battle against Ebola

    Group says world is losing battle against Ebola

    Tuesday, September 2 2014 11:12 PM EDT2014-09-03 03:12:17 GMT
    The U.N. is warning that food prices are rising in countries hit by Ebola and that it'll get worse because many farmers won't be able to access fields during the upcoming harvests of rice and corn.More >>
    The international group Doctors Without Borders warned Tuesday that the world is losing the battle against Ebola and lamented that treatment centers in West Africa have been "reduced to places where people go to die alone."More >>
  • Preschools latest to take on green movement

    Preschools latest to take on green movement

    Tuesday, September 2 2014 6:21 PM EDT2014-09-02 22:21:33 GMT
    A new Oklahoma City preschool is staying away from plastic toys, serving only vegan and gluten-free food, and focusing on teaching children early about living a healthy lifestyle.More >>
    Three-year-old Clara Centola seems unconcerned by the adults around her as she works at a mini-kitchen, deciding which cloth-toy fruits and vegetables to serve her imaginary guests. There are no plastic fast-food replicas...More >>

WASHINGTON (AP) - The Food and Drug Administration on Monday approved a Johnson & Johnson tuberculosis drug that is the first new medicine to fight the deadly infection in more than four decades.

The agency approved J&J's pill, Sirturo, for use with older drugs to fight a hard-to-treat strain of tuberculosis that has not responded to other medications. However, the agency cautioned that the drug carries risks of potentially deadly heart problems and should be prescribed carefully by doctors.

Roughly one-third of the world's population is estimated to be infected with the bacteria causing tuberculosis. The disease is rare in the U.S., but kills about 1.4 million people a year worldwide. Of those, about 150,000 succumb to the increasingly common drug-resistant forms of the disease. About 60 percent of all cases are concentrated in China, India, Russia and Eastern Europe.

Sirturo, known chemically as bedaquiline, is the first medicine specifically designed for treating multidrug-resistant tuberculosis. That's a form of the disease that cannot be treated with at least two of the four primary antibiotics used for tuberculosis.

The standard drugs used to fight the disease were developed in the 1950s and 1960s.

"The antibiotics used to treat it have been around for at least 40 years and so the bacterium has become more and more resistant to what we have," said Chrispin Kambili, global medical affairs leader for J&J's Janssen division.

The drug carries a boxed warning indicating that it can interfere with the heart's electrical activity, potentially leading to fatal heart rhythms.

"Sirturo provides much-needed treatment for patients who have don't have other therapeutic options available," said Edward Cox, director of the FDA's antibacterial drugs office. "However, because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don't have other treatment options."

Nine patients taking Sirturo died in company testing compared with two patients taking a placebo. Five of the deaths in the Sirturo group seemed to be related to tuberculosis, but no explanation was apparent for the remaining four.

Despite the deaths, the FDA approved the drug under its accelerated approval program, which allows the agency to clear innovative drugs based on promising preliminary results.

Last week, the consumer advocacy group Public Citizen criticized that approach, noting the drug's outstanding safety issues.

"The fact that bedaquiline is part of a new class of drug means that an increased level of scrutiny should be required for its approval," the group states. "But the FDA had not yet answered concerns related to unexplained increases in toxicity and death in patients getting the drug."

The FDA said it approved the drug based on two mid-stage studies enrolling 440 patients taking Sirturo. Both studies were designed to measure how long it takes patients to be free of tuberculosis.

Results from the first trial showed most patients taking Sirturo plus older drugs were cured after 83 days, compared with 125 days for those taking a placebo plus older drugs. The second study showed most Sirturo patients were cured after 57 days.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WXOW. All Rights Reserved.
For more information on this site, please read our Privacy Policy, Terms of Service and Mobile Privacy Policy & Terms of Service.

Persons with disabilities who need assistance with issues relating to the content of this station's public inspection file should contact Administrative Assistant Theresa Wopat at 507-895-9969. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, at 888-835-5322 (TTY) or at fccinfo@fcc.gov.